Nephros Therapeutics changes name to RenaMed Biologics

By Jennifer Chiou

New York, Sept. 27 - Nephros Therapeutics announced it changed its name to RenaMed Biologics.

The company said it altered its name to reflect its focus on diseases involving severely compromised kidney function.

"After pioneering technology development in renal cell biology, we have just completed a controlled, multi-center phase II clinical trial of Renal Bio-Replacement Therapy for treatment of acute renal failure, data from which will be presented at the end of this year," chairman and chief executive officer Greg Phelps said in a news release.

The Lincoln, R.I.-based clinical-stage company's Bio-Replacement Therapy replaces the biologic functions of the kidney lost in patients with acute renal failure.

The company also said it will present the Phase II clinical results of its Bio-Replacement Therapy at the American Society of Nephrology annual meeting.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.